MERCK: INTISMERAN PLUS KEYTRUDA REDUCED RECURRENCE/DEATH RISK BY 58%, REDUCED RISK OF DISTANT METASTASIS/DEATH BY HALF AT 6 MONTHS VS KEYTRUDA ALONE

Reuters · 2d ago

Please log in to view news